Amgen Presents Encouraging PCSK9 Inhibitor Repatha Data
March 17, 2015 at 10:14 AM EDT
Amgen Inc. (AMGN) presented encouraging one-year data from the phase II (OSLER-1) and phase III (OSLER-2) open-label extension studies and phase III YUKAWA-2 study on its PCSK9 inhibitor.
